Update in General Internal Medicine: Evidence Published in 2012
Authors: Matthew Rusk, Robert K. Cato
Journal: Annals of Internal Medicine (2013)

Updates16 April 2013Update in General Internal Medicine: Evidence Published in 2012Matthew Rusk, MD and Robert K. Cato, MDMatthew Rusk, MDFrom University of Pennsylvania, Philadelphia, Pennsylvania.Search for more papers by this author and Robert K. Cato, MDFrom University of Pennsylvania, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-158-8-201304160-00101 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The year 2012 saw the publication of important studies that will help general internists provide high-value care. In the case of controversial screening tests, such as prostate-specific antigen (PSA) measurement, the debate continues as to whether we should use the test at all. A definitive answer may never be reached, but 2 new studies add to the evidence that PSA screening has a minimal effect on mortality and carries the potential for substantial harm. New technologies may make colorectal cancer screening easier for the patient and hopefully increase screening rates, which have improved very slowly in past years. Important advancements ...References1. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med. 2004;350:2558-63. [PMID: 15201412] CrossrefMedlineGoogle Scholar2. Eichinger S, Minar E, Bialonczyk C, Hirschl M, Quehenberger P, Schneider B, et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA. 2003;290:1071-4. [PMID: 12941680] CrossrefMedlineGoogle Scholar3. Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med. 1997;336:393-8. [PMID: 9010144] CrossrefMedlineGoogle Scholar4. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-75. [PMID: 18579811] CrossrefMedlineGoogle Scholar5. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-9. [PMID: 21900088] CrossrefMedlineGoogle Scholar6. Eikelboom JW, Connolly SJ. Warfarin in heart failure [Editorial]. N Engl J Med. 2012;366:1936-8. [PMID: 22551103] CrossrefMedlineGoogle Scholar7. Johnson CD, Chen MH, Toledano AY, Heiken JP, Dachman A, Kuo MD, et al. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med. 2008;359:1207-17. [PMID: 18799557] CrossrefMedlineGoogle Scholar8. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al; PLCO Project Team. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125-32. [PMID: 22228146] CrossrefMedlineGoogle Scholar9. McNaughton-Collins MF, Barry MJ. One man at a time—resolving the PSA controversy. N Engl J Med. 2011;365:1951-3. [PMID: 22029758] CrossrefMedlineGoogle Scholar10. Wolters T, Roobol MJ, Steyerberg EW, van den Bergh RC, Bangma CH, Hugosson J, et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer. 2010;126:2387-93. [PMID: 19739124] MedlineGoogle Scholar11. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:762-71. [PMID: 21984740] LinkGoogle Scholar12. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-99. [PMID: 21091279] CrossrefMedlineGoogle Scholar13. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341-52. [PMID: 21481449] CrossrefMedlineGoogle Scholar14. Nguyen NT, Masoomi H, Magno CP, Nguyen XM, Laugenour K, Lane J. Trends in use of bariatric surgery, 2003-2008. J Am Coll Surg. 2011;213:261-6. [PMID: 21624841] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From University of Pennsylvania, Philadelphia, Pennsylvania.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M13-0259.Corresponding Author: Matthew Rusk, MD, University of Pennsylvania, Penn Presbyterian Medical Center, Penn Center for Primary Care, Medical Arts Building, 3900 Filbert Street, Suite 102, Philadelphia, PA 19104.Current Author Addresses: Drs. Rusk and Cato: University of Pennsylvania, Penn Presbyterian Medical Center, Penn Center for Primary Care, Medical Arts Building, 3900 Filbert Street, Suite 102, Philadelphia, PA 19104.Author Contributions: Conception and design: M. Rusk, R.K. Cato.Critical revision of the article for important intellectual content: M. Rusk, R.K. Cato.This article was published at www.annals.org on 11 April 2013. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 16 April 2013Volume 158, Issue 8Page: 615-619KeywordsAspirinBariatric surgeryColonoscopyHeart failureMortalityObesityOverweightProstate cancerSurgeryWeight loss ePublished: 16 April 2013 Issue Published: 16 April 2013 Copyright & PermissionsCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...